Anixa Biosciences Inc. (ANIX)
Anixa Biosciences Inc. (ANIX) Stock Price, Analysis & Data
| Bid | 2.37 |
| Market Cap | 111.6M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.03M |
| Beta | 0.52 |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | n/a |
| Forward PE | -10.58 |
| P/B (ttm) | 7.68 |
| P/S (ttm) | n/a |
| Earnings Date | Sep 9, 2026 |
| Ask | 4.12 |
| Volume | 92,013 |
| Avg. Volume (20D) | 224,337 |
| Open | 3.21 |
| Previous Close | 3.22 |
| Day's Range | 3.20 - 3.33 |
| 52-Week Range | 2.32 - 5.46 |
| Analyst | n/a |
| Price Target | 9.5 (189.63%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast canc...
Financial Performance
In 2025, Anixa Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.93M, a decrease of -12.96%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for ANIX stock is "null". The 12-month stock price forecast is 9.5, which is upside of 189.63% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
1 month ago · Pharmaceutical Technology
Anixa Biosciences secures Korean patent for breast cancer vaccineThe patent expands Anixa’s IP portfolio beyond the US and existing international markets.
